RxDoctor Payments Data

Barry Butler, MD

Internal Medicine · Woodbury, NJNPI 1770581449

Payments from drug & device makers

$484in general payments, 2019–2025

Across 27 payments — averaging $17.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$148
  • Lilly USA, LLC$121
  • Otsuka America Pharmaceutical, Inc.$62
  • Insulet Corporation$26
  • Grifols USA, LLC$20
  • AbbVie$18
  • plus $89 from 6 others

What the payments were for

  • Food & beverage$484100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$484 in reported general payments places this provider in the 55th percentile of 4,032 internal medicine providers in New Jersey.

See all internal medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$640,109
Medicare patients
543
Services billed
16,635

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban169$152,658
OzempicSemaglutide44$76,672
JanuviaSitagliptin Phosphate50$55,300
XareltoRivaroxaban51$50,691
JardianceEmpagliflozin46$45,437
Trelegy ElliptaFluticasone/Umeclidin/Vilanter30$26,796
MounjaroTirzepatide13$26,007
EntrestoSacubitril/Valsartan21$17,369
MyrbetriqMirabegron25$13,784
CreonLipase/Protease/Amylase19$12,110
Tresiba Flextouch U-100Insulin Degludec12$8,921
TradjentaLinagliptin15$8,502
Dexlansoprazole DrDexlansoprazole15$7,209
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen125$5,513
Fluticasone-SalmeterolFluticasone Propion/Salmeterol26$4,438

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$148$76,67244 claims
MerckJanuvia$15$55,30050 claims
Boehringer IngelheimJardiance, Tradjenta$16$53,93961 claims
Lilly USA, LLCMounjaro$121$26,00713 claims
AbbVieCreon, Synthroid$18$14,01337 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 4,032 internal medicine providers in New Jersey.

Other internal medicine in Woodbury

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →